▼ -9.31% Downside Potential
This price target is based on 15 analysts offering 12 month price targets for Mirati Therapeutics in the last 3 months. The average price target is $163.43, with a high forecast of $222.00 and a low forecast of $85.00. The average price target represents a -9.31% upside from the last price of $180.20.
The current consensus among 15 investment analysts is to buy stock in Mirati Therapeutics.
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. It is developing MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.